ColoRectal Cancer – Stratification of Therapies through Adaptive Responses (CRC‑STARS)
A five-year international research project investigating how different bowel cancers respond to current treatments, why certain bowel cancers spread, and whether we can predict which treatments will work for individual patients.
Years
Institutes
Researchers
Funding
Clinical Trials
Funders
Stratifying therapy through adaptive response
Colorectal cancer (CRC) remains the second most common cause of cancer death. It presents an opportunity for precision medicine: it is common, has known driver molecular pathways, and pre-treatment molecular stratification is achievable.
Recent single-cell studies show CRC tumours are made up of multiple populations within a complex microenvironment. In addition, data from preclinical models show tumour cells are highly plastic, adapting to therapy in ways that may underpin both response and resistance.
The project
The aim of the project is to test recent discoveries from pre-clinical models in patient samples from 3 neo-adjuvant clinical trials; FOxTROT, TREC and PRIME-RT. Serial sampling (blood and tumour) will be analysed using state of the art technologies and correlated to response which can then be re-tested in laboratory models and re-interrogated in clinical data. The team believe that by using this “bedside, to bench, and back to bedside” approach to understanding how cancer behaves at a molecular and cellular level will allow us to personalise CRC treatment in the future.
Leadership
Owen Sansom
Network Lead
CRUK Scotland Institute, Glasgow
Jenny Seligmann
Co-Lead
University of Leeds
Simon Leedham
Co-Lead
University of Oxford
Jointly funded, awarded March 2025
Over 50 researchers with expertise in different disciplines, at institutes across the UK, Spain (Spanish Association Against Cancer Scientific Foundation), Italy and Belgium.
Project Coordinator — Fiona Paulin-Ali
For enquiries about the CRC-STARS programme, get in touch.
Email me




